pharma Β· Alopecia areata Β· Multiple myeloma
First Biotech (Australia)
Pfizer Australia Pty Ltd
First Biotech (Australia) clinical programs β 126 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Norwest House, 710 Collins Street, Melbourne, VIC 3008, AU
- Founded
- 2017
- Employees
- 2
- Programs
- 126
- Drugs
- 208
- Patents
- 0
First Biotech (Australia) projects
126 ClinicalTrials.gov programs sponsored by First Biotech (Australia).
First Biotech (Australia) has 126 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
A5481092
Pfizer Australia Pty Ltd
recurrent/refractory Ewing sarcoma, recurrent or refractory neuroblastoma
1 trial -
B1791094
Pfizer Australia Pty Ltd
EROSIVE ESOPHAGITIS
1 trial -
B1931036
Pfizer Australia Pty Ltd
Acute Lymphoblastic Leukemia (ALL)
1 trial -
B7981118
Pfizer Australia Pty Ltd
CHRONIC SPONTANEOUS URTICARIA
1 trial -
B7981119
Pfizer Australia Pty Ltd
HIDRADENITIS SUPPURATIVA
1 trial -
C1131003
Pfizer Australia Pty Ltd
Primary immune thrombocytopenia
1 trial -
C3601010
Pfizer Australia Pty Ltd
Sepsis, Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment, Complicated Urinary Tract Infection, Blood Stream Infection, Hospital-acquired pneumonia or ventilator-associated pneumonia, Complicated Intra-abdominal Infection
1 trial -
C3651003
Pfizer Australia Pty Ltd
Cancer cachexia
1 trial -
C3651011
Pfizer Australia Pty Ltd
Heart failure
1 trial -
C4161001
Pfizer Australia Pty Ltd
Breast Cancer, Ovarian Cancer, SCLC (Part 1 also had TNBC and NSCLC)
1 trial -
C4221008
Pfizer Australia Pty Ltd
Non-small Cell Lung Cancer
1 trial -
C4221022
Pfizer Australia Pty Ltd
MSI-H/dMMR metastatic colorectal cancer
1 trial -
C4221023
Pfizer Australia Pty Ltd
Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma
1 trial -
C4391025
Pfizer Australia Pty Ltd
HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER
1 trial -
C4531002
Pfizer Australia Pty Ltd
Moderate-Severe Atopic Dermatitis
1 trial -
C4531029
Pfizer Australia Pty Ltd
Moderate-to-severe Asthma
1 trial -
C4921003
Pfizer Australia Pty Ltd
Heart failure
1 trial -
C4971006
Pfizer Australia Pty Ltd
Relapsed/Refractory Diffuse Large B Cell Lymphoma
1 trial -
C5041018
Pfizer Australia Pty Ltd
Ulcerative Colitis
1 trial -
C5541010
Pfizer Australia Pty Ltd
Obesity, Overweight
1 trial -
C6231002
Pfizer Australia Pty Ltd
Atopic Dermatitis
1 trial -
C6461008
Pfizer Australia Pty Ltd
ADVANCED OR METASTATIC RENAL CELL CARCINOMA
1 trial -
C6461013
Pfizer Australia Pty Ltd
Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma
1 trial -
CT7001, PF-07850327 round
Pfizer Australia Pty Ltd
Advanced or Metastatic Breast Cancer
1 trial -
Disitamab Vedotin
Pfizer Australia Pty Ltd
HER2 Expressing Advanced Breast Cancer
1 trial -
ELRANATAMAB
Pfizer Australia Pty Ltd
Multiple myeloma
1 trial -
FULVESTRANT, LETROZOLE
Pfizer Australia Pty Ltd
HR-positive HER2-negative metastatic/advanced BC
1 trial -
LETROZOLE, FULVESTRANT
Pfizer Australia Pty Ltd
Part 2A, 2B, 2C & 2E HR-positive /HER2-negative breast cancer, Part 1F Prostate cancer, Part 2D mCRPC, Part 1A/Part 1D/Part1E Breast cancer, NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification., Part 1B &1C HR-positive/HER2-negative breast cancer
1 trial -
PF-07850327 round
Pfizer Australia Pty Ltd
ADVANCED OR METASTATIC BREAST CANCER
1 trial -
PF-07868489
Pfizer Australia Pty Ltd
Pulmonary Arterial Hypertension
1 trial -
Sigvotatug vedotin, PF-08634404
Pfizer Australia Pty Ltd
Advanced Solid Tumors
1 trial -
A Study of PF-08046031 in Adults With Advanced Melanoma and Other Solid Tumors
Pfizer Australia Pty Ltd
Melanoma (or) malignant melanoma Non-small cell lung cancer Head and neck squamous cell carcinoma Esophageal cancer
1 trial -
A Study to Learn If the Study Medicine Called...
Pfizer Australia Pty Ltd
ER+/HER2 positive breast cancer
1 trial -
A0281007
Pfizer Australia Pty Ltd
Primary and secondary hypertension, and heart failure
1 trial -
A6281331
Pfizer Australia Pty Ltd
Growth hormone deficiency
1 trial -
A6791042
Pfizer Australia Pty Ltd
long-term female contraception
1 trial -
B3461114
Pfizer Australia Pty Ltd
aransthyretin amyloid cardiomyopathy
1 trial -
B3461115
Pfizer Australia Pty Ltd
Transthyretin amyloidosis
1 trial -
B3461131
Pfizer Australia Pty Ltd
Transthyretin amyloidosis
1 trial -
C2321001
Pfizer Australia Pty Ltd
Castration Resistant Prostate Cancer (CRPC), Follicular Lymphoma (FL), Small Cell Lung Cancer (SCLC), Diffuse Large B-Cell Lymphoma (DLBCL)
1 trial -
C2321006
Pfizer Australia Pty Ltd
Small cell lung cancer, Castration-resistant prostate cancer, Follicular lymphoma
1 trial -
C2321007
Pfizer Australia Pty Ltd
small cell lung cancer (SCLC), castration resistant prostate cancer (CRPC), follicular lymphoma (FL)
1 trial -
C3421063
Pfizer Australia Pty Ltd
Type 2 Diabetes Mellitus, Obesity, Overweight management
1 trial -
C4151006
Pfizer Australia Pty Ltd
Inflammatory bowel disease
1 trial -
C4151008
Pfizer Australia Pty Ltd
Inflammatory bowel disease.
1 trial -
C4161006
Pfizer Australia Pty Ltd
(HR) -positive human epidermal growth factor receptor 2 (HER2) -negative breast cancer (BC), non-small cell lung cancer (NSCLC), ovarian cancer, and triple negative breast cancer (TNBC)
1 trial -
C4391010
Pfizer Australia Pty Ltd
metastatic/advanced breast cancer
1 trial -
C4541011
Pfizer Australia Pty Ltd
Older adults at risk of malnutrition
1 trial
Frequently asked questions
How many clinical projects does First Biotech (Australia) have?
126 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.